Elicio Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Elicio Therapeutics, Inc. (ELTX) reported Deferred Federal Income Tax Expense (Benefit) of -$11.24 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2025-03-31
- Elicio Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$11.24M, a 245.11% decline from fiscal 2023.
- Elicio Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $7.74M, a 50.00% increase from fiscal 2022.
- Elicio Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $5.16M.
- Elicio Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2021 was -$5.46M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$11.24M 10-K · filed 2025-03-31 | |
| 2023-12-31 | $7.74M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $5.16M 10-K · filed 2024-03-29 | -$6.71M 10-K · filed 2023-03-17 |
| 2021-12-31 | -$5.46M 10-K · filed 2023-03-17 | |
| 2020-12-31 | -$12.13M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |